The Harvard Adult ACTU has several clinical centers for trials of promising drugs and drug strategies in the treatment of HIV infection or its complications. Main sites include the Massachusetts General Hospital (MGH), Beth Israel Deaconess Medical Center (BIDMC), and Boston Medical Center (BMC). An ancillary site will be the Brigham and Women's Hospital (BWH). This collaborative group draws from a wide patient catchment area in Massachusetts and throughout New England, including all socio-economic groups. Both sexes are represented and there is a wide diversity of racial and ethnic groups included in studies. All adult risk groups participate, and the number of under-represented and minority population participants has risen steadily in recent years. Studies are conducted on antiretroviral agents, and drugs active against opportunistic pathogens. Studies also are conducted on the pathogenesis of HIV infections, and on the effects of treatment strategies on the natural history of infection. Studies of the metabolic complications of HIV infection and its therapy also are underway. Individuals are studied at all stages of infection, and the current application proposes to extend these studies and to broaden the involvement of under-represented populations in HIV clinical trials. The Harvard Adult ACTU has made contributions to existing knowledge concerning the pathogenesis and therapy of HIV infection, and has contributed to the Scientific Agenda and leadership of the existing ACTG. Harvard has participated in the ACTG Quality Control program since its inception and is conducting critical studies on viral resistance and quantitation, and immunopathogenesis. This Unit plans to expand these research efforts within the framework of the ACTG Advanced Technology Laboratory Program.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI027659-17
Application #
6626472
Study Section
Special Emphasis Panel (ZAI1-PSS-A (S1))
Program Officer
Matula, Margaret A
Project Start
1992-04-01
Project End
2004-12-31
Budget Start
2003-01-01
Budget End
2003-12-31
Support Year
17
Fiscal Year
2003
Total Cost
$1,624,923
Indirect Cost
Name
Harvard University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
02115
Bisson, Gregory P; Ramchandani, Ritesh; Miyahara, Sachiko et al. (2017) Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults. AIDS 31:2217-2225
Sacktor, Ned; Miyahara, Sachiko; Evans, Scott et al. (2014) Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment. J Neurovirol 20:620-6
Erlandson, Kristine M; Kitch, Douglas; Tierney, Camlin et al. (2013) Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density. AIDS 27:2069-79
Gandhi, Rajesh T; Bosch, Ronald J; Aga, Evgenia et al. (2013) Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173. Antivir Ther 18:607-13
Taiwo, Babafemi; Acosta, Edward P; Ryscavage, Patrick et al. (2013) Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study. J Acquir Immune Defic Syndr 64:167-73
Wohl, David A; Kendall, Michelle A; Feinberg, Judith et al. (2013) The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit. PLoS One 8:e78676
Chang, J Judy; Woods, Matt; Lindsay, Robert J et al. (2013) Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication. J Infect Dis 208:830-8
Robbins, Gregory K; Testa, Marcia A; Su, Max et al. (2013) Site nurse-initiated adherence and symptom support telephone calls for HIV-positive individuals starting antiretroviral therapy, ACTG 5031: substudy of ACTG 384. HIV Clin Trials 14:235-53
Sacktor, N; Miyahara, S; Deng, L et al. (2011) Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology 77:1135-42
Bhattacharya, Debika; Umbleja, T; Carrat, F et al. (2010) Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis. J Acquir Immune Defic Syndr 55:170-5

Showing the most recent 10 out of 88 publications